- Home
- ETON vs GLRE Comparison
ETON vs GLRE Comparison
Compare ETON & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- GLRE
- Stock Information
- Founded
- ETON 2017
- GLRE 2004
- Country
- ETON United States
- GLRE Cayman Islands
- Employees
- ETON N/A
- GLRE N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- GLRE Property-Casualty Insurers
- Sector
- ETON Health Care
- GLRE Finance
- Exchange
- ETON Nasdaq
- GLRE Nasdaq
- Market Cap
- ETON 498.8M
- GLRE 439.8M
- IPO Year
- ETON 2018
- GLRE 2007
- Fundamental
- Price
- ETON $16.95
- GLRE $13.27
- Analyst Decision
- ETON Strong Buy
- GLRE
- Analyst Count
- ETON 3
- GLRE 0
- Target Price
- ETON $29.67
- GLRE N/A
- AVG Volume (30 Days)
- ETON 278.7K
- GLRE 127.8K
- Earning Date
- ETON 11-06-2025
- GLRE 11-03-2025
- Dividend Yield
- ETON N/A
- GLRE N/A
- EPS Growth
- ETON N/A
- GLRE N/A
- EPS
- ETON N/A
- GLRE N/A
- Revenue
- ETON $70,316,000.00
- GLRE $661,540,000.00
- Revenue This Year
- ETON $105.25
- GLRE N/A
- Revenue Next Year
- ETON $40.84
- GLRE N/A
- P/E Ratio
- ETON N/A
- GLRE N/A
- Revenue Growth
- ETON 102.77
- GLRE N/A
- 52 Week Low
- ETON $8.43
- GLRE $11.57
- 52 Week High
- ETON $23.00
- GLRE $15.38
- Technical
- Relative Strength Index (RSI)
- ETON 38.74
- GLRE 65.36
- Support Level
- ETON $16.34
- GLRE $11.57
- Resistance Level
- ETON $18.15
- GLRE $13.27
- Average True Range (ATR)
- ETON 1.08
- GLRE 0.31
- MACD
- ETON -0.14
- GLRE 0.14
- Stochastic Oscillator
- ETON 14.34
- GLRE 98.86
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.